knowledge -WSS

knowledge

author：focus 2025-09-29 20:17:34 - browse：7966

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How Vertex's cystic fibrosis drug is changing patients' lives

entertainment

leisure time

WSS

Lasker Awards 2023: Winners in biomedical research

AstraZeneca loses challenge to Medicare drug price negotiation

FDA does about

Change Healthcare cyberattack outage could last weeks

Obesity now affects over 1 billion people worldwide, study finds

CDC's new outbreak response network to include Northeastern

hotspot

knowledge

explore

Supreme Court strikes down use of affirmative action

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Sports medicine is finally prioritizing gender equality

Obesity now affects over 1 billion people worldwide, study finds

23andMe had bad news about my health. I wish a person had delivered it

Changes to biosimilar regulatory framework must prioritize patients

The high cost of giving birth even with insurance

In search for therapies for solid tumors, companies turn to claudin

Malaria cases in Florida and Texas: Here’s what you need to know

ALS groups 'won't be played again' by the FDA, drug sponsors

knowledge

Biotech companies concerned about China biosecurity crackdown

FogPharma raises $145 million in rare Series E round

Thermo Fisher plant for manufacturing gene therapies to expand

Biotech companies concerned about China biosecurity crackdown

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Change Healthcare cyberattack outage could last weeks

focus

entertainment

leisure time

explore